China Gears up to Change the Rules of the Game on Drug Sales
Sunday, May 10, 2015
Source: Fierce Pharma Asia
If China has its way, within another year or two, a repeat of the GlaxoSmithKline ($GSK) and similar scandals will be far less likely, but drugmakers can expect to face a harder sell as a result. The government just completed a comprehensive healthcare reform plan centered on the nation's public hospital system, but with a reach throughout the medical process.
The overall mix could provide the pharmaceutical industry with the prospect of getting some good while having to accept some bad. Healthcare subsidies are to be increased for the urban and rural poor, offering more sales targets, but drug prices are to remain heavily scrutinized along with the entire system of producing and distributing them.